Francois Schiele
Overview
Explore the profile of Francois Schiele including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
199
Citations
2915
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rossello X, Gonzalez-Del-Hoyo M, Aktaa S, Gale C, Barbash I, Claeys M, et al.
Eur Heart J Acute Cardiovasc Care
. 2025 Jan;
PMID: 39874263
Background: Closing the evidence-practice gap for the treatment of acute coronary syndrome (ACS) is central to improving quality of care. Under the European Society of Cardiology (ESC) framework, we aimed...
2.
Danchin N, Lemesle G, Mazighi M, Mohammedi K, Schiele F, Sibon I, et al.
BMJ Open
. 2025 Jan;
15(1):e087790.
PMID: 39788759
Introduction: Several cardiovascular outcome trials have been conducted to assess the cardiovascular safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on cardiorenal outcomes in patients with type-2 diabetes (T2D)....
3.
Chopard R, Vidoni C, Besutti M, Ismail M, Ecarnot F, Favoulet B, et al.
J Am Heart Assoc
. 2024 Sep;
13(19):e035143.
PMID: 39291476
Background: The optimal strategy in prosthetic heart valve thrombosis (PVT) remains controversial, with no randomized trials and conflicting observational data. We performed a systematic review and meta-analysis of evidence comparing...
4.
Tsaban G, Perez R, Krychtiuk K, Ahrens I, Halvorsen S, Hassager C, et al.
Coron Artery Dis
. 2024 Sep;
36(1):51-58.
PMID: 39263716
Background: Recent guidelines on acute coronary syndromes (ACS) recommend initiating lipid-lowering therapy (LLT) as early as possible to obtain >50% low-density-lipoprotein cholesterol (LDL-c) reduction and an LDL-c < 1.4 mmol/l....
5.
Scirica B, Lincoff A, Lingvay I, Bogdanski P, Buscemi S, Colhoun H, et al.
J Am Coll Cardiol
. 2024 Sep;
84(17):1632-1642.
PMID: 39217559
Background: Patients with overweight and obesity are at increased risk of death from multiple causes, including cardiovascular (CV) death, with few therapies proven to reduce the risk. Objectives: This study...
6.
Weizman O, Hauguel-Moreau M, Tea V, Albert F, Barragan P, Georges J, et al.
Eur J Prev Cardiol
. 2024 Aug;
31(15):1850-1860.
PMID: 39192488
Aims: Women are less likely to receive lipid-lowering therapy (LLT) after acute myocardial infarction (AMI). We analysed whether this under-prescription currently persists and has an impact on long-term outcomes. Methods...
7.
Bouisset F, Bataille V, Schiele F, Puymirat E, Fayol A, Simon T, et al.
Front Cardiovasc Med
. 2024 Jun;
11:1401569.
PMID: 38932992
Objective: The long-term impact of type 2 diabetes mellitus (T2DM) after an acute myocardial infarction (AMI) has not been thoroughly investigated yet. This study aimed to assess the long-term impact...
8.
Gautier A, Danchin N, Ducrocq G, Rousseau A, Cottin Y, Cayla G, et al.
Arch Cardiovasc Dis
. 2024 May;
117(6-7):417-426.
PMID: 38821761
Background: Despite major advances in prevention and treatment, cardiovascular diseases - particularly acute myocardial infarction - remain a leading cause of death worldwide and in France. Collecting contemporary data about...
9.
Dievart F, Bruckert E, Aboyans V, Bekka S, Boccara F, Bourdon Baron Munoz B, et al.
Arch Cardiovasc Dis
. 2024 May;
117(5):358-378.
PMID: 38762344
Low-density lipoprotein cholesterol has been established as a powerful cardiovascular risk factor; its reduction provides a clinical benefit in primary cardiovascular prevention, irrespective of the characteristics of the patients treated....
10.
Fayol A, Schiele F, Ferrieres J, Puymirat E, Bataille V, Tea V, et al.
Circ Cardiovasc Qual Outcomes
. 2024 Apr;
17(5):e010685.
PMID: 38682335
Background: Older people are underrepresented in randomized trials. The association between lipid-lowering therapy (LLT) and its intensity after acute myocardial infarction and long-term mortality in this population deserves to be...